Clinical Trial Update: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

A National Cancer Institute-sponsored Phase 1 trial evaluating adding ASTX660 (tolinapant) to eribulin for advanced triple-negative breast cancer has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ASTX660
• Halaven (eribulin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Status: WITHDRAWN